Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.

Abstract: RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.

Abstract: An intraocular lens (IOL) injection device is modularized to enable cleaning of internal components after surgery. The device includes first and second housing modules. These modules collectively define a passageway along which an injector rod moves between a retracted position and an extended position. The first module is further configured to accommodate a lens cartridge module. The cartridge module has disposed therein an IOL, in alignment with the passageway. Thus as the rod moves from the retracted position to the extended position, a front portion of the rod that is substantially surrounded by the first module in the retracted position moves into the cartridge module and displaces the IOL. This causes the front portion of the rod to accumulate on it viscoelastic substances. The first module, though, is configured to detach from the second module, to thereby expose the front portion of the rod in the retracted position for cleaning.

Abstract: An implantable ophthalmic power system includes a power source and an enclosure. The enclosure surrounds the power source. The enclosure is configured to be implanted under the conjunctiva of the eye.

Abstract: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs alone or in combination with histamine antagonists and/or mast cell stabilizers is disclosed for the treatment of ocular allergy.

Abstract: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.

Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.

Abstract: A small gauge pulsed electric field/aspirator probe. The probe has a generally cylindrical cannula with a generally smooth distal end. A port is located near a distal end of the cannula on a side of the cannula. A pair of electrodes is located at the port. An electric pulse generator is coupled to the pair of electrodes. A distance between the distal end of the cannula and the port is approximately equal to the distance between a back wall of Schlemm's canal and a trabecular meshwork in a human eye. The electric pulse generator applies a pulsed electric field to the pair of electrodes sufficient to dissociate protein bonds that hold the trabecular meshwork together.

Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.

Abstract: An ophthalmologic cutting device having a base support section for attachment with a movement generating device and a tip with a blade section. The blade section preferably has upper and lower edges, and a forward aspiration free edge extending between them, with the upper edge having a shorter longitudinal length compared with the lower edge and where the forward edge slopes down from a distal end of the upper edge to a distal end of the lower edge, and the lower edge presenting a material contact surface that is thinner in thickness than the upper edge. A slope back in the proximal direction of the forward edge of, for example, 10 to 45 degrees with a straight and/or curving forward edge or a combination of a straight and forward edge sections is preferred.

Abstract: An elastomeric acoustic coupler formed by molding a thermoplastic or silicone rubber into a recess of a surgical cassette housing. The coupling has a raised pad to aid in the removal of all air between the transducer and the fluid conduit, and to provide an efficient transmission of an ultrasound signal into the fluid conduit.

Abstract: The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed.

Abstract: The invention provides functionalized polypeptides, especially therapeutic polypeptides (e.g., scFv), comprising a linker sequence that can be rapidly and specifically functionalized by the addition of one or functional moieties (e.g., PEG) or binding specificities (e.g., an amino acid sequence with a particular binding specificity). Such functionalized polypeptides are advantageous in that they have improved pharmacokinetic properties (e.g., improved in vivo half-life, tissue penetration and tissue residency time) over non-functionalized polypeptides. Methods for the rapid and reproducible generation of functionalized polypeptides are also provided.

Abstract: An ablation probe for use in glaucoma surgery has a shaft, a heating element, and a pair of electrical connectors located on a distal end of the shaft. The pair of electrical connectors holds the heating element to the shaft. The heating element is sized and shaped to ablate a trabecular meshwork in a human eye. The ablation probe is advanced through a corneal incision until the heating element contacts the trabecular meshwork. An electrical current is passed through the heating element to ablate the trabecular meshwork.

Abstract: Compositions and methods for treating nasal disorders associated with nasal inflammation using a multipharmacophoric agent (MPA) that can prevent the production and/or release of at least one or more pro-inflammatory cytokines (for instance IL-1 and TNF?) and inhibit p38 MAP kinase or at least one matrix metalloproteinases (MMP-1 and MMP-9) are disclosed.

Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.

Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.

Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.

Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having or at risk of developing macular edema.